CYCLACEL PHARMACEUTICALS | 0,385 Euro | +0,015 +4,05 % | |
| WKN: A0JJ38 ISIN: US23254L1089 Ticker-Symbol: UXI1 | Frankfurt | 25.05.12 | 18:39 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 17.04. | Cyclacel Pharmaceuticals Announces Grant of New U.S. Patent Covering Sapacitabine | 2 | Benzinga.com | |
| 22.03. | Cyclacel (CYCC) Enters $3.04M Financing Agreement | - | StreetInsider.com | |
| 13.02. | Cyclacel (CYCC) Updates on Sapacitabine Caps Phase 2 | 5 | StreetInsider.com | |
| 08.12. | Oncothyreon and Cyclacel Pharmaceuticals -- Strong Examples of Recession Proof Growth / The Paragon Report Provides Equity Research on Oncothyreon & Cyclacel Pharmaceuticals | 31 | MarketWire | |
| NEW YORK, NY -- (Marketwire) -- 12/08/11 -- The Biotechnology industry has long been regarded as a "Recession Proof" sector of the economy. Even during periods of financial turmoil, most people will... Mehr lesen zu: Oncothyreon and Cyclacel Pharmaceuticals -- Strong Examples of Recession Proof Growth / The Paragon Report Provides Equity Research on Oncothyreon & Cyclacel Pharmaceuticals | ||||
| 07.12. | Cyclacel (CYCC) Reports Observation of PR, Stable Disease in Sapacitabine Phase 1, 2 in NSCLC Patients | 1 | StreetInsider.com | |
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
